Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;20(2):127-131.
doi: 10.1080/14656566.2018.1550071. Epub 2018 Dec 10.

Mipomersen and its use in familial hypercholesterolemia

Johnathon Seth Parham  1 , Anne Carol Goldberg  1
Affiliations
Review

Mipomersen and its use in familial hypercholesterolemia

Johnathon Seth Parham et al. Expert Opin Pharmacother. 2019 Feb.

Abstract

Familial Hypercholesterolemia (FH) is an inherited disorder characterized by a defect in the binding and internalization of low-density lipoprotein (LDL) particles, resulting in markedly elevated LDL levels and premature atherosclerosis. It is one of the most common inherited disorders of lipid metabolism. Many FH patients, especially those with homozygous FH do not reach LDL goals with traditional LDL therapies and may require additional, less often used, therapies. Areas covered: Mipomersen is an anti-sense oligonucleotide that prevents production of apolipoprotein B leading to decreased levels of very low-density lipoprotein (VLDL) and LDL. In this review the authors discuss the pharmacokinetics of the drug, the clinical trials evaluating its efficacy and safety, and risks and challenges associated with its clinical implementation. Its use as therapy for the treatment of FH is also discussed. Expert opinion: Mipomersen is approved for use only in homozygous FH. It has frequent adverse effects, such as injection site reactions, flu-like symptoms, and hepatoxicity. It is useful only in patients who have failed other therapies, and it faces competition from other medications that have more tolerable side effect profiles.

Keywords: Antisense oligonucleotide; familial hypercholesterolemia; lomitapide; mipomersen.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest

AC Goldberg has received clinical trial grants via his medical school from Genzyme, ISIS, IONIS, Merck & Co, Pfizer Inc, Amgen Inc, Regeneron, Sanofi/Regeneron, GlaxoSmithKline, Amarin Corporation, The Medicines Company and Genentech. She has also received honoraria for consultancy and/or serving on the advisory boards of Sanofi/Regeneron, Optum Rx, Esperion and uniQure. Furthermore, AC Goldberg has also received modest honoraria for editorial work for Merck & Co working with them on a manual. She also has board and committee memberships and has received speaker’s fees from the National Lipid Association, and has received speaker fees from the Endocrine Society. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Hopkins P, Toth P. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011. June;5(3 Suppl):S9–17. - PubMed
    1. Reiner Z Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol. 2015:12:565–75. - PubMed
    1. Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. Curr Atheroscler Rep. 2014. September;16(9):439. - PubMed

    1. Cuchel M, Bruckert E, Ginsberg H. Homozygous Familial Hypercholesterolaemia: New Insights and Guidance for Clinicians to Improve Detection and Clinical Management. Eur Heart J. 2014;35(32):2146–2157.

      **Important review of homozygous familial hypercholesterolemia providing suggested diagnostic criteria.

    1. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013. April 13;381(9874):1293–301. - PubMed

MeSH terms

LinkOut - more resources